{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:31:10Z","timestamp":1790958670178,"version":"4.1.0"},"reference-count":94,"publisher":"Bentham Science Publishers Ltd.","issue":"5","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["PNT"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>The potential use of nanoparticle-based formulations is being explored rapidly for drug\ndelivery in ocular treatment. Despite having several advancements in the area of ocular therapy,\nthe pharmacokinetics-based formulation development for pediatric ocular treatment is still not in\nproper focus. There are an inadequate number of degenerative ocular ailments with childhood\nonset. The purpose of this review is to focus on the pharmacokinetics studies of nanoparticle-\nbased formulations for treating ocular diseases and problems associated with the ocular treatment\nof the pediatric population. Recent studies on pharmaceutical modeling of ocular formulations\nhave also been discussed. Nanoparticle-based formulations were collected by conducting a\nliterature survey on PubMed, Science Direct, and other portals. In this review, we have explored\nin detail the explanation behind the inequality among available ocular treatment regimens for\nyoungsters as well as adults by specifically focusing on those diseases that can be distressing for\nchildren. Latest innovative developments and advancements in drug delivery systems and challenges\nin their usage particularly for young infant patients were also discussed. It can be concluded\nthat the bioavailability of ocular formulations and their effect on ocular cells can be further enhanced\nmanifolds by the development of nanoparticles-based formulations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/0122117385307184240826041920","type":"journal-article","created":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T05:09:57Z","timestamp":1727413797000},"page":"885-895","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A Review on Ocular Nanoformulation Based Formulations with Highlights on Pediatric Ocular Pharmacokinetics"],"prefix":"10.2174","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3397-703X","authenticated-orcid":true,"given":"Ravinder","family":"Verma","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Sciences, Chaudhary Bansi Lal University, Bhiwani, 127021, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manisha","family":"Bhatia","sequence":"additional","affiliation":[{"name":"MM College ofPharmacy, Maharishi Markandeshwar (Deemed to be University), Mullana, Ambala, Haryana, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mithun","family":"Mojumder","sequence":"additional","affiliation":[{"name":"MM College ofPharmacy, Maharishi Markandeshwar (Deemed to be University), Mullana, Ambala, Haryana, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suraj","family":"Patel","sequence":"additional","affiliation":[{"name":"MM College ofPharmacy, Maharishi Markandeshwar (Deemed to be University), Mullana, Ambala, Haryana, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek Kumar","family":"Mishra","sequence":"additional","affiliation":[{"name":"MM College ofPharmacy, Maharishi Markandeshwar (Deemed to be University), Mullana, Ambala, Haryana, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pooja","family":"Mathur","sequence":"additional","affiliation":[{"name":"Department ofPharmacy, School of Medical and Allied Sciences, G D Goenka University, Sohna, Gurugram, Haryana, 122103, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shailendra","family":"Bhatt","sequence":"additional","affiliation":[{"name":"Shrinathji Institute of Pharmacy, Shrinathji Society for Higher Education, Upali Oden, Nathdwara, Rajasmand(Rajasthan), India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jai Bharti","family":"Sharma","sequence":"additional","affiliation":[{"name":"MM College ofPharmacy, Maharishi Markandeshwar (Deemed to be University), Mullana, Ambala, Haryana, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.addr.2019.08.008","volume":"151-152","author":"Yellepeddi V.K.","year":"2019","unstructured":"Yellepeddi V.K.; Joseph A.; Nance E.; Pharmacokinetics of nanotechnology-based formulations in pediatric populations. Adv Drug Deliv Rev  2019,151-152,44-55","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1136\/archdischild-2015-308227","volume":"101","author":"van Riet-Nales D.A.","year":"2016","unstructured":"van Riet-Nales D.A.; Schobben A.F.A.M.; Vromans H.; Egberts T.C.G.; Rademaker C.M.A.; Safe and effective pharmacotherapy in infants and preschool children: Importance of formulation aspects. Arch Dis Child  2016,101(7),662-669","journal-title":"Arch Dis Child"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"518","DOI":"10.3390\/pharmaceutics11100518","volume":"11","author":"Gerrard S.E.","year":"2019","unstructured":"Gerrard S.E.; Walsh J.; Bowers N.; Salunke S.; Hershenson S.; Innovations in pediatric drug formulations and administration technologies for low resource settings. Pharmaceutics  2019,11(10),518","journal-title":"Pharmaceutics"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/1471-2431-12-8","volume":"12","author":"Fortinguerra F.","year":"2012","unstructured":"Fortinguerra F.; Clavenna A.; Bonati M.; Ocular medicines in children: The regulatory situation related to clinical research. BMC Pediatr  2012,12(1),8-20","journal-title":"BMC Pediatr"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.3109\/03639045.2012.736515","volume":"39","author":"Achouri D.","year":"2013","unstructured":"Achouri D.; Alhanout K.; Piccerelle P.; Andrieu V.; Recent advances in ocular drug delivery. Drug Dev Ind Pharm  2013,39(11),1599-1617","journal-title":"Drug Dev Ind Pharm"},{"key":"ref=6","doi-asserted-by":"crossref","first-page":"028","DOI":"10.29328\/journal.hps.1001005","volume":"1","author":"John M","year":"2017","unstructured":"John M; Gacche RN; Nano-formulations for ophthalmic treatments. Arch Pharm Pharma Sci  2017,1,028-035","journal-title":"Arch Pharm Pharma Sci"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"460","DOI":"10.3390\/pharmaceutics11090460","volume":"11","author":"Souto E.B.","year":"2019","unstructured":"Souto E.B.; Dias-Ferreira J.; L\u00f3pez-Machado A.; Ettcheto M.; Cano A.; Camins Espuny A.; Espina M.; Garcia M.L.; S\u00e1nchez-L\u00f3pez E.; Advanced formulation approaches for ocular drug delivery: State-of-the-art and recent patents. Pharmaceutics  2019,11(9),460","journal-title":"Pharmaceutics"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1111\/j.1475-1313.1991.tb00193.x","volume":"11","author":"Tomlinson A.","year":"1991","unstructured":"Tomlinson A.; Trees G.R.; Occhipinti J.R.; Tear production and evaporation in the normal eye. Ophthalmic Physiol Opt  1991,11(1),44-47","journal-title":"Ophthalmic Physiol Opt"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1208\/s12248-010-9183-3","volume":"12","author":"Gaudana R.","year":"2010","unstructured":"Gaudana R.; Ananthula H.K.; Parenky A.; Mitra A.K.; Ocular drug delivery. AAPS J  2010,12(3),348-360","journal-title":"AAPS J"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1007\/s13346-016-0339-2","volume":"6","author":"Agrahari V.","year":"2016","unstructured":"Agrahari V.; Mandal A.; Agrahari V.; Trinh H.M.; Joseph M.; Ray A.; Hadji H.; Mitra R.; Pal D.; Mitra A.K.; A comprehensive insight on ocular pharmacokinetics. Drug Deliv Transl Res  2016,6(6),735-754","journal-title":"Drug Deliv Transl Res"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s40123-020-00229-x","volume":"9","author":"Suzuki G.","year":"2020","unstructured":"Suzuki G.; Kunikane E.; Shinno K.; Kozai S.; Kurata M.; Kawamura A.; Ocular and systemic pharmacokinetics of brimonidine and timolol after topical administration in rabbits: Comparison between fixed-combination and single drugs. Ophthalmol Ther  2020,9(1),115-125","journal-title":"Ophthalmol Ther"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.exer.2017.10.021","volume":"167","author":"Gough G.","year":"2018","unstructured":"Gough G.; Szapacs M.; Shah T.; Clements P.; Struble C.; Wilson R.; Ocular tissue distribution and pharmacokinetic study of a small 13kDa domain antibody after intravitreal, subconjuctival and eye drop administration in rabbits. Exp Eye Res  2018,167,14-17","journal-title":"Exp Eye Res"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.ejpb.2015.02.032","volume":"96","author":"Ruponen M.","year":"2015","unstructured":"Ruponen M.; Urtti A.; Undefined role of mucus as a barrier in ocular drug delivery. Eur J Pharm Biopharm  2015,96,442-446","journal-title":"Eur J Pharm Biopharm"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.survophthal.2003.12.009","volume":"49","author":"Van Santvliet L.","year":"2004","unstructured":"Van Santvliet L.; Ludwig A.; Determinants of eye drop size. Surv Ophthalmol  2004,49(2),197-213","journal-title":"Surv Ophthalmol"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1136\/bjo.76.11.681","volume":"76","author":"McGhee C.N.","year":"1992","unstructured":"McGhee C.N.; Pharmacokinetics of ophthalmic corticosteroids. Br J Ophthalmol  1992,76(11),681-684","journal-title":"Br J Ophthalmol"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1016\/j.cclet.2017.07.022","volume":"28","author":"Sheybani N.D.","year":"2017","unstructured":"Sheybani N.D.; Yang H.; Pediatric ocular nanomedicines: Challenges and opportunities. Chin Chem Lett  2017,28(9),1817-1821","journal-title":"Chin Chem Lett"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"287","DOI":"10.3341\/kjo.2017.0142","volume":"33","author":"Shahid E.","year":"2019","unstructured":"Shahid E.; Shaikh A.; Aziz S.; Rehman A.; Frequency of ocular diseases in infants at a tertiary care hospital. Korean J Ophthalmol  2019,33(3),287-293","journal-title":"Korean J Ophthalmol"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.2147\/OPTH.S118409","volume":"10","author":"Farkouh A.","year":"2016","unstructured":"Farkouh A.; Frigo P.; Czejka M.; Systemic side effects of eye drops: A pharmacokinetic perspective. Clin Ophthalmol  2016,10,2433-2441","journal-title":"Clin Ophthalmol"},{"key":"ref=19","first-page":"171","volume":"13","author":"Patton T.F.","year":"1976","unstructured":"Patton T.F.; Robinson J.R.; Pediatric dosing considerations in ophthalmology. J Pediatr Ophthalmol  1976,13(3),171-178","journal-title":"J Pediatr Ophthalmol"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1002\/jps.2600650742","volume":"65","author":"Friedman T.S.","year":"1976","unstructured":"Friedman T.S.; Patton T.F.; Differences in ocular penetration of pilocarpine in rabbits of different ages. J Pharm Sci  1976,65(7),1095-1096","journal-title":"J Pharm Sci"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1007\/s00417-012-2097-2","volume":"251","author":"Han S.B.","year":"2013","unstructured":"Han S.B.; Yang H.K.; Hyon J.Y.; Hwang J.M.; Children with dry eye type conditions may report less severe symptoms than adult patients. Graefes Arch Clin Exp Ophthalmol  2013,251(3),791-796","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1517\/17425247.2011.542142","volume":"8","author":"du Toit L.C.","year":"2011","unstructured":"du Toit L.C.; Pillay V.; Choonara Y.E.; Govender T.; Carmichael T.; Ocular drug delivery \u2013 A look towards nanobioadhesives. Expert Opin Drug Deliv  2011,8(1),71-94","journal-title":"Expert Opin Drug Deliv"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1016\/j.ophtha.2013.01.018","volume":"120","author":"Dua H.S.","year":"2013","unstructured":"Dua H.S.; Faraj L.A.; Said D.G.; Gray T.; Lowe J.; Human corneal anatomy redefined: A novel pre-Descemet\u2019s layer (Dua\u2019s layer). Ophthalmology  2013,120(9),1778-1785","journal-title":"Ophthalmology"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.drudis.2013.10.001","volume":"19","author":"Almeida H.","year":"2014","unstructured":"Almeida H.; Amaral M.H.; Lob\u00e3o P.; Lobo J.M.S.; In situ gelling systems: A strategy to improve the bioavailability of ophthalmic pharmaceutical formulations. Drug Discov Today  2014,19(4),400-412","journal-title":"Drug Discov Today"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1089\/jop.1994.10.217","volume":"10","author":"Salazar-Bookaman M.M.","year":"1994","unstructured":"Salazar-Bookaman M.M.; Wainer I.; Patil P.N.; Relevance of drug-melanin interactions to ocular pharmacology and toxicology. J Ocul Pharmacol Ther  1994,10(1),217-239","journal-title":"J Ocul Pharmacol Ther"},{"key":"ref=26","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1533\/9781908818317.229","author":"Barot M.","year":"2013","unstructured":"Barot M.; Patel M.; Kwatra D.; Mitra A.K.; Transporter\u2013metabolism interplay in the eye. Ocular Transporters and Receptors  2013,229-248","journal-title":"Ocular Transporters and Receptors"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1533\/9781908818317.37","author":"Dhananjay P.","year":"2013","unstructured":"Dhananjay P.; Ramya Krishna V.; Aswani Dutt V.; Mitra A.K.; Biology of ocular transporters: Efflux and influx transporters in the eye. Ocular transporters and receptors  2013,37-84","journal-title":"Ocular transporters and receptors"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"117","DOI":"10.22270\/jddt.v7i6.1512","volume":"7","author":"Ramesh Y.","year":"2017","unstructured":"Ramesh Y.; Kothapalli C.B.; Reddigari J.R.P.; A novel approaches on Ocular drug delivery system. J Drug Deliv Ther  2017,7(6),117-124","journal-title":"J Drug Deliv Ther"},{"key":"ref=29","first-page":"1","volume":"2","author":"Kumaran K.S.","year":"2010","unstructured":"Kumaran K.S.; Karthika K.; Padmapreetha J.; Comparative review on conventional and advanced ocular drug delivery formulations. Int J Pharm Pharm Sci  2010,2(4),1-5","journal-title":"Int J Pharm Pharm Sci"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1002\/1522-2594(200009)44:3<433::AID-MRM14>3.0.CO;2-9","volume":"44","author":"Anderson S.A.","year":"2000","unstructured":"Anderson S.A.; Rader R.K.; Westlin W.F.; Null C.; Jackson D.; Lanza G.M.; Wickline S.A.; Kotyk J.J.; Magnetic resonance contrast enhancement of neovasculature with? v?3-targeted nanoparticles. Magn Reson Med  2000,44(3),433-439","journal-title":"Magn Reson Med"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"4691","DOI":"10.1021\/ma010005w","volume":"34","author":"Dong C.M.","year":"2001","unstructured":"Dong C.M.; Qiu K.Y.; Gu Z.W.; Feng X.D.; Synthesis of Star-Shaped Poly(\u03b5-caprolactone)- b -poly(  -lactic acid- alt -glycolic acid) with Multifunctional Initiator and Stannous Octoate Catalyst. Macromolecules  2001,34(14),4691-4696","journal-title":"Macromolecules"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.1002\/jps.20685","volume":"95","author":"Vega E.","year":"2006","unstructured":"Vega E.; Egea M.A.; Valls O.; Espina M.; Garc\u00eda M.L.; Flurbiprofen loaded biodegradable nanoparticles for ophtalmic administration. J Pharm Sci  2006,95(11),2393-2405","journal-title":"J Pharm Sci"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s12645-010-0006-0","volume":"1","author":"Parveen S.","year":"2010","unstructured":"Parveen S.; Sahoo S.K.; Evaluation of cytotoxicity and mechanism of apoptosis of doxorubicin using folate-decorated chitosan nanoparticles for targeted delivery to retinoblastoma. Cancer Nanotechnol  2010,1(1-6),47-62","journal-title":"Cancer Nanotechnol"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1208\/s12249-014-0072-4","volume":"15","author":"Yang X.","year":"2014","unstructured":"Yang X.; Patel S.; Sheng Y.; Pal D.; Mitra A.K.; Statistical design for formulation optimization of hydrocortisone butyrate-loaded PLGA nanoparticles. AAPS PharmSciTech  2014,15(3),569-587","journal-title":"AAPS PharmSciTech"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"92","DOI":"10.3390\/biomedicines6030092","volume":"6","author":"Kelly S.J.","year":"2018","unstructured":"Kelly S.J.; Hirani A.; Shahidadpury V.; Solanki A.; Halasz K.; Varghese Gupta S.; Madow B.; Sutariya V.; Aflibercept nanoformulation inhibits VEGF expression in ocular in vitro model: A preliminary report. Biomedicines  2018,6(3),92","journal-title":"Biomedicines"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1073\/pnas.1525796113","volume":"113","author":"Hosoya H.","year":"2016","unstructured":"Hosoya H.; Dobroff A.S.; Driessen W.H.P.; Cristini V.; Brinker L.M.; Staquicini F.I.; Card\u00f3-Vila M.; D\u2019Angelo S.; Ferrara F.; Proneth B.; Lin Y.S.; Dunphy D.R.; Dogra P.; Melancon M.P.; Stafford R.J.; Miyazono K.; Gelovani J.G.; Kataoka K.; Brinker C.J.; Sidman R.L.; Arap W.; Pasqualini R.; Integrated nanotechnology platform for tumor-targeted multimodal imaging and therapeutic cargo release. Proc Natl Acad Sci USA  2016,113(7),1877-1882","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"255","DOI":"10.3390\/gels8050255","volume":"8","author":"Gilani S.J.","year":"2022","unstructured":"Gilani S.J.; Jumah M.N.; Zafar A.; Imam S.S.; Yasir M.; Khalid M.; Alshehri S.; Ghuneim M.M.; Albohairy F.M.; Formulation and evaluation of nano lipid carrier-based ocular gel system: Optimization to antibacterial activity. Gels  2022,8(5),255","journal-title":"Gels"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.2147\/IJN.S360740","volume":"17","author":"Youssef A.A.A.","year":"2022","unstructured":"Youssef A.A.A.; Dudhipala N.; Majumdar S.; Dual drug loaded lipid nanocarrier formulations for topical ocular applications. Int J Nanomedicine  2022,17,2283-2299","journal-title":"Int J Nanomedicine"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.3390\/molecules27041328","volume":"27","author":"Santonocito D.","year":"2022","unstructured":"Santonocito D.; Vivero-Lopez M.; Lauro M.R.; Torrisi C.; Castelli F.; Sarpietro M.G.; Puglia C.; Design of nanotechnological carriers for ocular delivery of mangiferin: Preformulation study. Molecules  2022,27(4),1328","journal-title":"Molecules"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.3390\/pharmaceutics14071328","volume":"14","author":"Kalam M.A.","year":"2022","unstructured":"Kalam M.A.; Iqbal M.; Alshememry A.; Alkholief M.; Alshamsan A.; Fabrication and characterization of tedizolid phosphate nanocrystals for topical ocular application: Improved solubilization and in vitro drug release. Pharmaceutics  2022,14(7),1328","journal-title":"Pharmaceutics"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.ejpb.2022.02.010","volume":"172","author":"Varela-Fern\u00e1ndez R.","year":"2022","unstructured":"Varela-Fern\u00e1ndez R.; Garc\u00eda-Otero X.; D\u00edaz-Tom\u00e9 V.; Regueiro U.; L\u00f3pez-L\u00f3pez M.; Gonz\u00e1lez-Barcia M.; Isabel Lema M.; Javier Otero-Espinar F.; Lactoferrin-loaded nanostructured lipid carriers (NLCs) as a new formulation for optimized ocular drug delivery. Eur J Pharm Biopharm  2022,172,144-156","journal-title":"Eur J Pharm Biopharm"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.3390\/pharmaceutics14081557","volume":"14","author":"Jacinto T.A.","year":"2022","unstructured":"Jacinto T.A.; Oliveira B.; Miguel S.P.; Ribeiro M.P.; Coutinho P.; Ciprofloxacin-loaded zein\/hyaluronic acid nanoparticles for ocular mucosa delivery. Pharmaceutics  2022,14(8),1557","journal-title":"Pharmaceutics"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1080\/10717544.2022.2100513","volume":"29","author":"Nemr A.A.","year":"2022","unstructured":"Nemr A.A.; El-Mahrouk G.M.; Badie H.A.; Hyaluronic acid-enriched bilosomes: An approach to enhance ocular delivery of agomelatine via D-optimal design: Formulation, in vitro characterization, and in vivo pharmacodynamic evaluation in rabbits. Drug Deliv  2022,29(1),2343-2356","journal-title":"Drug Deliv"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.3390\/pharmaceutics14061246","volume":"14","author":"Youssef A.A.A.","year":"2022","unstructured":"Youssef A.A.A.; Thakkar R.; Senapati S.; Joshi P.H.; Dudhipala N.; Majumdar S.; Design of topical moxifloxacin mucoadhesive nanoemulsion for the management of ocular bacterial infections. Pharmaceutics  2022,14(6),1246","journal-title":"Pharmaceutics"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.3390\/pharmaceutics14091975","volume":"14","author":"Hamed R.","year":"2022","unstructured":"Hamed R.; Abu Kwiak A.D.; Al-Adhami Y.; Hammad A.M.; Obaidat R.; Abusara O.H.; Huwaij R.A.; Microemulsions as lipid nanosystems loaded into thermoresponsive in situ microgels for local ocular delivery of prednisolone. Pharmaceutics  2022,14(9),1975","journal-title":"Pharmaceutics"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"2428","DOI":"10.1080\/10717544.2022.2103600","volume":"29","author":"Ahmed S.","year":"2022","unstructured":"Ahmed S.; Amin M.M.; El-Korany S.M.; Sayed S.; Corneal targeted fenticonazole nitrate-loaded novasomes for the management of ocular candidiasis: Preparation, in vitro characterization, ex vivo and in vivo assessments. Drug Deliv  2022,29(1),2428-2441","journal-title":"Drug Deliv"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"103","DOI":"10.5281\/zenodo.5875144","volume":"74","author":"Bhattacharyya S","year":"1997","unstructured":"Bhattacharyya S; Rana D; Bhattacharyya SN; Determination of heat of formation of associated systems by calorimetry. J Indian Chem Soc  1997,74(2),103-107","journal-title":"J Indian Chem Soc"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"456","DOI":"10.5281\/zenodo.5880620","volume":"74","author":"Bhattacharyya S","year":"1997","unstructured":"Bhattacharyya S; Rana D; Bhattacharyya SN; A thermodynamic study of molecular association by gas liquid chromatography. J Indian Chem Soc  1997,74(6),456-463","journal-title":"J Indian Chem Soc"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"548","DOI":"10.5281\/zenodo.5901630","volume":"74","author":"Bhatacharyya S","year":"1997","unstructured":"Bhatacharyya S; Rana D; Bhattacharyya SN; A Thermodynamic study of molecular association by gas-liquid chromatography: trilaurylamine-alcohol systems. J Indian Chem Soc  1997,74(7),548-551","journal-title":"J Indian Chem Soc"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1002\/(SICI)1099-0488(20000201)38:3<369::AID-POLB3>3.0.CO;2-W","volume":"38","author":"Rana D.","year":"2000","unstructured":"Rana D.; Bag K.; Bhattacharyya S.N.; Mandal B.M.; Miscibility of poly(styrene-co-butyl acrylate) with poly(ethyl methacrylate): Existence of both UCST and LCST. J Polym Sci, B, Polym Phys  2000,38(3),369-375","journal-title":"J Polym Sci, B, Polym Phys"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1016\/0032-3861(96)85356-0","volume":"37","author":"Rana D.","year":"1996","unstructured":"Rana D.; Mandal B.M.; Bhattacharyya S.N.; Analogue calorimetry of polymer blends: Poly(styrene-co-acrylonitrile) and poly(phenyl acrylate) or poly(vinyl benzoate). Polymer (Guildf)  1996,37(12),2439-2443","journal-title":"Polymer (Guildf)"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1016\/0032-3861(93)90861-4","volume":"34","author":"Rana D.","year":"1993","unstructured":"Rana D.; Mandal B.M.; Bhattacharyya S.N.; Miscibility and phase diagrams of poly(phenyl acrylate) and poly(styrene-co-acrylonitrile) blends. Polymer  1993,34(7),1454-1459","journal-title":"Polymer"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"4062","DOI":"10.1021\/ma00200a043","volume":"22","author":"Bhattacharya C.","year":"1989","unstructured":"Bhattacharya C.; Maiti N.; Mandal B.M.; Bhattacharyya S.N.; Thermodynamic characterization of miscible blends from very similar polymers by inverse gas chromatography. The poly(ethyl acrylate)-poly(vinyl propionate) system. Macromolecules  1989,22(10),4062-4068","journal-title":"Macromolecules"},{"key":"ref=54","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/B978-0-12-814029-1.00015-6","author":"Singh A.K.","year":"2019","unstructured":"Singh A.K.; Yadav T.P.; Pandey B.; Gupta V.; Singh S.P.; Engineering nanomaterials for smart drug release: Recent advances and challenges. Applications of Targeted Nano Drugs and Delivery Systems  2019,411-449","journal-title":"Applications of Targeted Nano Drugs and Delivery Systems"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.2174\/1567201819666220519125003","volume":"20","author":"Verma R.","year":"2023","unstructured":"Verma R.; Mittal V.; Pandey P.; Bhatia S.; Bhatia M.; Karavasili C.; Behl T.; Al-Harrasi A.; Tagde P.; Kumar M.; Kaushik D.; Exploring the role of self-nanoemulsifying systems in drug delivery: Challenges, issues, applications and recent advances. Curr Drug Deliv  2023,20(9),1241-1261","journal-title":"Curr Drug Deliv"},{"key":"ref=56","author":"Simonnet JT","year":"2002","unstructured":"Simonnet JT; Sonneville O; Legret S; Nanoemulsion based on ethoxylated fatty ethers or on ethoxylated fatty esters and its uses in the cosmetics, dermatological and\/or ophthalmological.  2002"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"20180108","DOI":"10.1515\/jbcpp-2018-0108","volume":"30","author":"Patnaik S.K.","year":"2019","unstructured":"Patnaik S.K.; Halder N.; Chawla B.; Maithani D.; Thavaraj V.; Biswas N.R.; Velpandian T.; Comparison of ocular pharmacokinetics of etoposide and its nanoemulsion after subtenon administration in rabbits. J Basic Clin Physiol Pharmacol  2019,30(5),20180108","journal-title":"J Basic Clin Physiol Pharmacol"},{"key":"ref=58","volume":"1247","author":"Henostroza MA","year":"2020","unstructured":"Henostroza MA; Melo KJ; Yukuyama MN; L\u00f6benberg R; Bou-Chacra NA; Cationic rifampicin nanoemulsion for the treatment of ocular tuberculosis. Colloids Surf A  2020,1247","journal-title":"Colloids Surf A"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"75","DOI":"10.2174\/1574885517666220822104652","volume":"18","author":"Kaushik D.","year":"2023","unstructured":"Kaushik D.; Rani A.; Verma R.; Mittal V.; Bhatt S.; Kumar M.; Tiwari A.; Tiwari V.; Pandey P.; Formulation development and optimization of rosuvastatin loaded nanosuspension for enhancing dissolution rate. Curr Drug Ther  2023,18(1),75-87","journal-title":"Curr Drug Ther"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"56","DOI":"10.2174\/2211738503666150630185230","volume":"3","author":"Boddeda B.","year":"2015","unstructured":"Boddeda B.; Boddu P.; Avasarala H.; Jayanti V.; Design and ocular tolerance of flurbiprofen loaded nanosuspension. Pharm Nanotechnol  2015,3(1),56-67","journal-title":"Pharm Nanotechnol"},{"key":"ref=61","first-page":"213","volume":"5","author":"El-Feky G.S.","year":"2013","unstructured":"El-Feky G.S.; Zayed G.A.; Farrag A.R.; Optimization of an ocular nanosuspension formulation for acyclovir using factorial design. Int J Pharm Pharm Sci  2013,5(1),213-219","journal-title":"Int J Pharm Pharm Sci"},{"key":"ref=62","doi-asserted-by":"publisher","DOI":"10.2174\/1872210517666230731091046","volume":"17","author":"Kaushik D.","year":"2023","unstructured":"Kaushik D.; Verma R.; Kumar K.; Bhatt S.; Yadav M.; Kumar M.; Tagde P.; Rajinikanth P.S.; Tiwari A.; Tiwari V.; Nagpal D.; Mittal V.; Untangling breast cancer: Trailing towards nanoformulations-based drug development. Recent Pat Nanotechnol  2023,17","journal-title":"Recent Pat Nanotechnol"},{"key":"ref=63","doi-asserted-by":"publisher","DOI":"10.2174\/0118722105244482231017102857","volume":"18","author":"Verma R.","year":"2023","unstructured":"Verma R.; Rao L.; Kumar H.; Bansal N.; Deep A.; Parashar J.; Yadav M.; Mittal V.; Kaushik D.; Applications of nanomedicine in brain tumor therapy: Nanocarrier based drug delivery platforms, challenges, and perspectives. Recent Pat Nanotechnol  2023,18","journal-title":"Recent Pat Nanotechnol"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/0169-409X(95)00016-Z","volume":"16","author":"Meisner D.","year":"1995","unstructured":"Meisner D.; Mezei M.; Liposome ocular delivery systems. Adv Drug Deliv Rev  1995,16(1),75-93","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s12951-019-0498-7","volume":"17","author":"Lai S.","year":"2019","unstructured":"Lai S.; Wei Y.; Wu Q.; Zhou K.; Liu T.; Zhang Y.; Jiang N.; Xiao W.; Chen J.; Liu Q.; Yu Y.; Liposomes for effective drug delivery to the ocular posterior chamber. J Nanobiotechnology  2019,17(1),64","journal-title":"J Nanobiotechnology"},{"key":"ref=66","doi-asserted-by":"publisher","DOI":"10.2174\/1872210517666230613154847","author":"Verma R.","year":"2023","unstructured":"Verma R.; Rao L.; Nagpal D.; Yadav M.; Kumar V.; Kumar V.; Kumar H.; Parashar J.; Bansal N.; Kumar M.; Pandey P.; Mittal V.; Kaushik D.; Emerging nanotechnology-based therapeutics: A new insight into promising drug delivery system for lung cancer therapy. Recent Pat Nanotechnol  2023","journal-title":"Recent Pat Nanotechnol"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"S129","DOI":"10.1016\/S0039-6257(02)00303-X","volume":"47","author":"Enyedi L.B.","year":"2002","unstructured":"Enyedi L.B.; Freedman S.F.; Latanoprost for the treatment of pediatric glaucoma. Surv Ophthalmol  2002,47(Suppl. 1),S129-S132","journal-title":"Surv Ophthalmol"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1080\/03639045.2020.1755305","volume":"46","author":"Fathalla D.","year":"2020","unstructured":"Fathalla D.; Fouad E.A.; Soliman G.M.; Latanoprost niosomes as a sustained release ocular delivery system for the management of glaucoma. Drug Dev Ind Pharm  2020,46(5),806-813","journal-title":"Drug Dev Ind Pharm"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"483","DOI":"10.2217\/nnm-2023-0355","volume":"19","author":"Milivojevi\u0107 N.","year":"2024","unstructured":"Milivojevi\u0107 N.; Carvalho M.R.; Caballero D.; Radisavljevi\u0107 S.; Radoi\u0107i\u0107 M.; \u017divanovi\u0107 M.; Kundu S.C.; Reis R.L.; Filipovi\u0107 N.; Oliveira J.M.; Evaluation of novel dendrimer-gold complex nanoparticles for theranostic application in oncology. Nanomedicine  2024,19(6),483-497","journal-title":"Nanomedicine"},{"key":"ref=70","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/732340","volume":"2013","author":"Yavuz B","year":"2013","unstructured":"Yavuz B; Bozda\u011f Pehlivan S; \u00dcnl\u00fc N.; Dendrimeric systems and their applications in ocular drug delivery. Sci World J  2013,2013","journal-title":"Sci World J"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.jconrel.2004.09.015","volume":"102","author":"Vandamme T.F.","year":"2005","unstructured":"Vandamme T.F.; Brobeck L.; Poly(amidoamine) dendrimers as ophthalmic vehicles for ocular delivery of pilocarpine nitrate and tropicamide. J Control Release  2005,102(1),23-38","journal-title":"J Control Release"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.2174\/1381612826666200218101231","volume":"26","author":"L\u00f3pez E.S.","year":"2020","unstructured":"L\u00f3pez E.S.; Machado A.L.L.; Vidal L.B.; Gonz\u00e1lez-Pizarro R.; Silva A.D.; Souto E.B.; Lipid nanoparticles as carriers for the treatment of neurodegeneration associated with Alzheimer\u2019s disease and glaucoma: Present and future challenges. Curr Pharm Des  2020,26(12),1235-1250","journal-title":"Curr Pharm Des"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"228","DOI":"10.2174\/1872210516666220317143351","volume":"17","author":"Minocha N.","year":"2023","unstructured":"Minocha N.; Sharma N.; Verma R.; Kaushik D.; Pandey P.; Solid lipid nanoparticles: Peculiar strategy to deliver bio-proactive molecules. Recent Pat Nanotechnol  2023,17(3),228-242","journal-title":"Recent Pat Nanotechnol"},{"key":"ref=74","first-page":"1","author":"Yadav M.","year":"2020","unstructured":"Yadav M.; Schiavone N.; Aranguez A.I.; Giansanti F.; Papucci L.; Perez de Lara M.J.; Singh M.; Kaur I.P.; Atorvastatin-loaded solid lipid nanoparticles as eye drops: Proposed treatment option for age-related macular degeneration (AMD). Drug Deliv Transl Res  2020,1-26","journal-title":"Drug Deliv Transl Res"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"16668","DOI":"10.1039\/C7RA00552K","volume":"7","author":"Yu S.","year":"2017","unstructured":"Yu S.; Tan G.; Liu D.; Yang X.; Pan W.; Nanostructured lipid carrier (NLC)-based novel hydrogels as potential carriers for nepafenac applied after cataract surgery for the treatment of inflammation: Design, characterization and in vitro cellular inhibition and uptake studies. RSC Advances  2017,7(27),16668-16677","journal-title":"RSC Advances"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"679","DOI":"10.3390\/pharmaceutics11120679","volume":"11","author":"L Kiss E.","year":"2019","unstructured":"L Kiss E.; Berk\u00f3 S.; G\u00e1csi A.; Kov\u00e1cs A.; Katona G.; So\u00f3s J.; Cs\u00e1nyi E.; Gr\u00f3f I.; Harazin A.; Deli M.A.; Budai-Sz\u0171cs M.; Design, optimization of nanostructured lipid carrier containing dexamethasone for ophthalmic use. Pharmaceutics  2019,11(12),679","journal-title":"Pharmaceutics"},{"key":"ref=77","first-page":"321","volume":"56","author":"Shin C.","year":"2015","unstructured":"Shin C.; Marcano D.; Henriksson J.; Acharya G.; Pflugfelder S.C.; Nanowafer drug delivery for restoration of healthy ocular surface in dry eye condition. Invest Ophthalmol Vis Sci  2015,56(7),321","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/j.jconrel.2023.01.018","volume":"354","author":"Onugwu A.L.","year":"2023","unstructured":"Onugwu A.L.; Nwagwu C.S.; Onugwu O.S.; Echezona A.C.; Agbo C.P.; Ihim S.A.; Emeh P.; Nnamani P.O.; Attama A.A.; Khutoryanskiy V.V.; Nanotechnology based drug delivery systems for the treatment of anterior segment eye diseases. J Control Release  2023,354,465-488","journal-title":"J Control Release"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"3346","DOI":"10.1167\/iovs.08-2826","volume":"50","author":"Ciolino J.B.","year":"2009","unstructured":"Ciolino J.B.; Hoare T.R.; Iwata N.G.; Behlau I.; Dohlman C.H.; Langer R.; Kohane D.S.; A drug-eluting contact lens. Invest Ophthalmol Vis Sci  2009,50(7),3346-3352","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"225","DOI":"10.22270\/jddt.v12i2-S.5301","volume":"12","author":"Chaudhary R.","year":"2022","unstructured":"Chaudhary R.; Mishra R.; Nano-formulations: Recent trends for ocular bioavailability enhancement. J Drug Deliv Ther  2022,12(2-S),225-233","journal-title":"J Drug Deliv Ther"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.ijpharm.2013.03.024","volume":"448","author":"Li X.","year":"2013","unstructured":"Li X.; Zhang Z.; Chen H.; Development and evaluation of fast forming nano-composite hydrogel for ocular delivery of diclofenac. Int J Pharm  2013,448(1),96-100","journal-title":"Int J Pharm"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.jhazmat.2016.10.070","volume":"324","author":"Xin S.","year":"2017","unstructured":"Xin S.; Zeng Z.; Zhou X.; Luo W.; Shi X.; Wang Q.; Deng H.; Du Y.; Recyclable Saccharomyces cerevisiae loaded nanofibrous mats with sandwich structure constructing via bio-electrospraying for heavy metal removal. J Hazard Mater  2017,324(Pt B),365-372","journal-title":"J Hazard Mater"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1080\/17425247.2016.1218460","volume":"14","author":"Thakur Singh R.R.","year":"2017","unstructured":"Thakur Singh R.R.; Tekko I.; McAvoy K.; McMillan H.; Jones D.; Donnelly R.F.; Minimally invasive microneedles for ocular drug delivery. Expert Opin Drug Deliv  2017,14(4),525-537","journal-title":"Expert Opin Drug Deliv"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"187","DOI":"10.3109\/10717541003667798","volume":"17","author":"Donnelly R.F.","year":"2010","unstructured":"Donnelly R.F.; Singh T.R.R.; Woolfson A.D.; Microneedle-based drug delivery systems: Microfabrication, drug delivery, and safety. Drug Deliv  2010,17(4),187-207","journal-title":"Drug Deliv"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"82","DOI":"10.3390\/gels8020082","volume":"8","author":"Akhter M.H.","year":"2022","unstructured":"Akhter M.H.; Ahmad I.; Alshahrani M.Y.; Al-Harbi A.I.; Khalilullah H.; Afzal O.; Altamimi A.S.A.; Najib Ullah S.N.M.; Ojha A.; Karim S.; Drug delivery challenges and current progress in nanocarrier-based ocular therapeutic system. Gels  2022,8(2),82","journal-title":"Gels"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1007\/s11095-018-2556-5","volume":"36","author":"Mandal A.","year":"2019","unstructured":"Mandal A.; Gote V.; Pal D.; Ogundele A.; Mitra A.K.; Ocular pharmacokinetics of a topical ophthalmic nanomicellar solution of cyclosporine (Cequa\u00ae) for dry eye disease. Pharm Res  2019,36(2),36","journal-title":"Pharm Res"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1016\/j.nano.2017.04.008","volume":"13","author":"Campos E.J.","year":"2017","unstructured":"Campos E.J.; Campos A.; Martins J.; Ambr\u00f3sio A.F.; Opening eyes to nanomedicine: Where we are, challenges and expectations on nanotherapy for diabetic retinopathy. Nanomedicine  2017,13(6),2101-2113","journal-title":"Nanomedicine"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"5175","DOI":"10.2174\/1381612825666190130141310","volume":"24","author":"Mukker J.K.","year":"2019","unstructured":"Mukker J.K.; Singh R.S.P.; Pharmacokinetic modeling in nano-formulations: Concept, implementation and challenges. Curr Pharm Des  2019,24(43),5175-5180","journal-title":"Curr Pharm Des"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1208\/s12248-019-0334-x","volume":"21","author":"Le Merdy M.","year":"2019","unstructured":"Le Merdy M.; Fan J.; Bolger M.B.; Lukacova V.; Spires J.; Tsakalozou E.; Patel V.; Xu L.; Stewart S.; Chockalingam A.; Narayanasamy S.; Rouse R.; Matta M.; Babiskin A.; Kozak D.; Choi S.; Zhang L.; Lionberger R.; Zhao L.; Application of mechanistic ocular absorption modeling and simulation to understand the impact of formulation properties on ophthalmic bioavailability in rabbits: A case study using dexamethasone suspension. AAPS J  2019,21(4),65","journal-title":"AAPS J"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1002\/psp4.12421","volume":"8","author":"Zhao L.","year":"2019","unstructured":"Zhao L.; Seo P.; Lionberger R.; Current scientific considerations to verify physiologically\u2010based pharmacokinetic models and their implications for locally acting products. CPT Pharmacometrics Syst Pharmacol  2019,8(6),347-351","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s13318-016-0319-4","volume":"42","author":"Djebli N.","year":"2017","unstructured":"Djebli N.; Khier S.; Griguer F.; Coutant A.L.; Tavernier A.; Fabre G.; Leriche C.; Fabre D.; Ocular drug distribution after topical administration: population pharmacokinetic model in rabbits. Eur J Drug Metab Pharmacokinet  2017,42(1),59-68","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"2906","DOI":"10.1021\/acs.molpharmaceut.5b00729","volume":"13","author":"Vellonen K.S.","year":"2016","unstructured":"Vellonen K.S.; Soini E.M.; del Amo E.M.; Urtti A.; Prediction of ocular drug distribution from systemic blood circulation. Mol Pharm  2016,13(9),2906-2911","journal-title":"Mol Pharm"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1089\/jop.2016.0136","volume":"33","author":"Mori A.","year":"2017","unstructured":"Mori A.; Yabuta C.; Kishimoto Y.; Kozai S.; Ohtori A.; Shearer T.R.; Azuma M.; In silico ocular pharmacokinetic modeling: delivery of topical FK962 to retina. J Ocul Pharmacol Ther  2017,33(7),556-566","journal-title":"J Ocul Pharmacol Ther"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.exer.2015.05.003","volume":"137","author":"del Amo E.M.","year":"2015","unstructured":"del Amo E.M.; Urtti A.; Rabbit as an animal model for intravitreal pharmacokinetics: Clinical predictability and quality of the published data. Exp Eye Res  2015,137,111-124","journal-title":"Exp Eye Res"}],"container-title":["Pharmaceutical Nanotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0122117385307184240826041920","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/234547\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0122117385307184240826041920","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T07:17:30Z","timestamp":1762759050000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/234547\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":94,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0122117385307184240826041920","relation":{},"ISSN":["2211-7385"],"issn-type":[{"value":"2211-7385","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Double blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2024-03-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-24","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-04","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}